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SepsisIntroduction: Pneumococcus is an important respiratory pathogen. The 10-valent pneumococcal vaccine
(PHiD-CV) was introduced into the Icelandic vaccination programme in 2011. The aim was to estimate
the impact of PHiD-CV on paediatric hospitalisations for respiratory tract infections and invasive disease.
Methods: The 2005–2015 birth-cohorts were followed until three years of age and hospitalisations were
recorded for invasive pneumococcal disease (IPD), meningitis, sepsis, pneumonia and otitis media.
Hospitalisations for upper- and lower respiratory tract infections (URTI, LRTI) were used as comparators.
The 2005–2010 birth-cohorts were defined as vaccine non-eligible cohorts (VNEC) and 2011–2015 birth-
cohorts as vaccine eligible cohorts (VEC). Incidence rates (IR) were estimated for diagnoses, birth-cohorts
and age groups, and incidence rate ratios (IRR) between VNEC and VEC were calculated assuming Poisson
variance. Cox regression was used to estimate the hazard ratio (HR) of hospitalisation between VNEC and
VEC.
Results: 51,264 children were followed for 142,315 person-years, accumulating 1,703 hospitalisations for
the respective study diagnoses. Hospitalisations for pneumonia decreased by 20% (HR 0.80, 95%CI:0.67–
0.95) despite a 32% increase in admissions for LRTI (HR 1.32, 95%CI:1.14–1.53). Hospital admissions for
culture-confirmed IPD decreased by 93% (HR 0.07, 95%CI:0.01–0.50) and no hospitalisations for IPD with
vaccine-type pneumococci were observed in the VEC. Hospitalisations for meningitis and sepsis did not
change. A decrease in hospital admissions for otitis media was observed, but did not coincide with PHiD-
CV introduction.
Conclusion: Following the introduction of PHiD-CV in Iceland, hospitalisations for pneumonia and culture
confirmed IPD decreased. Admissions for other LRTIs and URTIs increased during this period.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Worldwide mortality in children under five years of age from
acute lower respiratory tract infections (LRTI) is estimated to be
105 per 100,000 children. More than half of the LRTI deaths are
estimated to be due to pneumonia caused by Streptococcus pneu-
moniae [1]. Mortality rates vary greatly between countries, ranging
from 0.65 to 547 per 100,000 children in Finland and Somalia,
respectively and have decreased by 37% globally since 2005 [1].
Hospitalisation rates also vary between countries. Immediatelybefore a pneumococcal conjugate vaccine (PCV) was introduced
into national immunization programmes, the rate of hospitalisa-
tions for pneumonia of children younger than two years of age
was 293, 615 and up to 1274 per 100,000 children in Scotland
[2], Sweden [3] and USA [4]. Pneumococci are the causative agent
of 9–30% of community-acquired pneumonia in children, and this
proportion is higher in severe pneumonia cases [5–9]. Pneumo-
cocci are also among the most common bacterial causes of menin-
gitis and sepsis in unvaccinated children, associated with high
morbidity and mortality [10]. Other clinical presentations of pneu-
mococcal infections, such as otitis media (OM) are more common
and less severe.
PCVs have been widely incorporated into national immuniza-
tion programmes in recent years, and have successfully reduced
2708 S. Sigurdsson et al. / Vaccine 38 (2020) 2707–2714invasive and non-invasive pneumococcal infections [2–4,11–17].
The 10-valent pneumococcal Haemophilus influenzae protein-D
conjugated vaccine (PHiD-CV) was introduced into the Icelandic
national immunisation programme in April 2011 for all children
born in January 2011 and later, in a 2 + 1 schedule without a
catch-up (at three, five and twelve months of age). Prior to the
introduction of PHiD-CV, no systematic pneumococcal vaccination
for children had been implemented. Vaccine uptake was excellent,
with >97% of children receiving the two primary doses before their
first birthday [18]. The aim of this study was to estimate the vac-
cine impact on admissions to the Children’s Hospital in Iceland
for culture-confirmed invasive pneumococcal disease (IPD), and
all-cause meningitis, sepsis, pneumonia and OM.2. Methods
2.1. Data sources
This study is a single-centre, individual-level, observational
cohort study of paediatric hospital admissions due to IPD and dis-
eases commonly caused by S. pneumoniae; all-cause OM, pneumo-
nia, sepsis and meningitis. Hospitalisations for lower respiratory
tract infections other than pneumonia (LRTI) and upper respiratory
tract infections other than otitis media (URTI), as well as all-cause
hospital admissions, were used as comparators. The Children’s
Hospital Iceland is the primary paediatric hospital for approxi-
mately 90% of the Icelandic population (www.statice.is) and serves
as a secondary and tertiary paediatric hospital for the entire
country.
Eleven consecutive Icelandic birth-cohorts 2005–2015 were fol-
lowed from birth to three years of age, or until the end of the study
period. Individual-level immigration and emigration data were col-
lected from Statistics Iceland. Children born outside of Iceland and
subsequently immigrated were excluded from the analysis. All
hospital admissions to the Children’s Hospital from 1 January
2005 to 31 December 2016 were included.
Data on admissions were collected from the hospital inpatient
registry. Seven diagnostic groups were defined, of which six were
based on International Classification of Diseases, 10th Revision
(ICD-10) discharge diagnoses (Table 1). Only one diagnosis per hos-
pital admission was used in the analysis. Diagnosis were sequen-
tially searched in the following order: meningitis, sepsis,
pneumonia, LRTI, AOM and finally URTI. An admission was consid-
ered to be due to IPD if the admitted child had culture- or PCR-
confirmed S. pneumoniae sampled from blood, cerebrospinal or
joint fluids and bones, regardless of ICD-10 discharge diagnosis.
These microbiological data were extracted from laboratory infor-
mation system of the Department of Clinical Microbiology at Land-
spitali University Hospital, the national reference laboratory for
Iceland.Table 1
Definition and summary of the study’s diagnostic groups. When applicable, the abbreviation
the International Classification of Diseases, 10th Revision (ICD-10) codes associated w





Otitis Media and Complications OM
Acute Upper Respiratory Tract Infections URTI
Acute Lower Respiratory Tract Infections LRTI
Invasive pneumococcal disease IPDUsing unique national identification numbers, culture data
were linked to admissions data at individual-level. Data included
date of birth, age, sex, the dates of admission and discharge, inten-
sive care unit (ICU) stay and discharge diagnosis. All positive cul-
tures linked to hospital admissions were included. Additionally,
aggregate data on all admissions to the Children’s Hospital Iceland,
regardless of diagnosis were collected and compared to the study
data.
Demographic information was collected from Statistics Iceland
(www.statice.is).
3. Statistical methods
All Icelandic children born 2005–2015 were followed from birth
until three years of age, death, emigration or the end of the study
period. Based on the eligibility criteria of the PHiD-CV programme,
birth-cohorts 2005–2010 were grouped as vaccine non-eligible
cohorts (VNEC) and birth-cohorts 2011–2015 as vaccine eligible
cohorts (VEC). When appropriate, the mean age at the time of
admission and the median length of hospitalisations were calcu-
lated and diagnostic groups compared using Welch’s two sample
t-test and Wilcoxon rank sum test, respectively. The crude inci-
dence rates (IR) of hospital admissions were calculated for each
birth-cohort, diagnostic group and age group, and crude incidence
rate ratios (IRR) were calculated between the VNEC and VEC
assuming Poisson variance. A sub-analysis was performed within
the pneumonia diagnostic group (ICD10: J10-J18), comparing each
code between the VNEC and VEC. The proportion of admissions
leading to an ICU stay was calculated by birth-cohort and diagnos-
tic group.
The Kaplan-Meier product limit estimator was used to calculate
the cumulative incidence of hospitalisations. This analysis included
only the first hospitalisation for each child according to diagnostic
group. For all other analyses, repeated hospitalisations were
included, except if they occurred within 30 days of a previous hos-
pitalisation for the same condition. Follow-up time was censored
on both emigration and death. An unadjusted Cox regression was
used to estimate the hazard ratio (HR) of hospitalisation between
the VNEC and VEC for each diagnostic group. To evaluate whether
the observed differences were likely to be due to direct effects of
the PHiD-CV, the Cox regression was repeated by stratifying the
data to two age-ranges; 0–90 days of age and 90 days and older.
The study was approved by The National Bioethics Committee
(VSNb2013010015/03.07), The National Data Protection Authority
(2013010100VEL/--) and medical director at the University
Hospital.
4. Results
Information was available for 53,228 children. Of those, 1892
were excluded because they had immigrated to Iceland after birth.used in the text is provided. Six of the seven diagnostic groups were defined based on
ith the hospitalisation. Invasive pneumococcal disease (IPD) was defined as any
r joint fluid.
Definition
ICD-10 discharge diagnosis of G00
ICD-10 discharge diagnosis of A41 or A42
ICD-10 discharge diagnosis of J09-J18
ICD-10 discharge diagnosis of H65, H66, H70 or H72
ICD-10 discharge diagnosis of J00-J06
ICD-10 discharge diagnosis of J20-J22
Microbiologically confirmed pneumococcal infection
from normally sterile site, regardless of ICD-10 diagnosis
S. Sigurdsson et al. / Vaccine 38 (2020) 2707–2714 2709A further 72 were excluded because of missing information on
birth-date. The remaining 51,264 children were followed for a
median of 1,096 days (range 6–1,096), resulting in 142,315
person-years of follow-up time. A total of 10,520 children had
the follow-up time censored before their third birthday. Of those,
8,234 were censored at the end of the study period, 2,263 were
censored due to emigration and 23 because of death. Birth-
cohorts ranged from 4,026 to 5,130 children, and 51.3% were male.
A total of 1,414 children were hospitalised 1,703 times for dis-
eases in the study’s diagnostic groups. The total number of admis-
sions, regardless of diagnosis, is shown in Table 2. Information on
age, gender, number of admissions, rate and length of hospital
and ICU admissions, stratified by study diagnosis and vaccine eligi-
bility are shown in supplementary Table 1.
4.1. Admissions due to pneumonia and LRTI other than pneumonia
During the study period, 550 children were admitted 660 times
with discharge diagnoses of pneumonia. Hospital admissions due
to LRTI (other than pneumonia) were recorded 550 times for 508
children. The crude IR of admissions for pneumonia among chil-
dren under three years of age was 4.94 and 4.18 per 1,000
person-years in the VNEC and VEC respectively. The corresponding
crude IR of admissions for other LRTI was 2.94 and 5.23 in the
VNEC and VEC respectively.
The crude IR for pneumonia admissions was highest in children
12–17 months of age, and significantly lower in the VEC compared
to the VNEC (crude IRR: 0.52 (95%CI: 0.35–0.77, Fig. 1). The IR of
admissions for LRTI was highest in children <6 months of age,
and was significantly higher in the VEC compared to the VNEC
(crude IRR 1.50, 95%CI 1.23–1.84, Fig. 1). The IR was not signifi-
cantly different in other age groups for both diagnoses (Fig. 1).
A significant reduction in admissions, for the ICD-10 diagnosis
pneumonia (organism unspecified, J18), was observed. The rates
of admissions for other ICD-10 discharge diagnoses within the
pneumonia diagnostic group did not differ significantly between
the cohorts (Table 3).
For both pneumonia hospitalisations and other LRTI, a clear dif-
ference in the cumulative admission rates per 1,000 person-years
was observed between VNEC and VEC (Fig. 2). The hazard ratio of
pneumonia hospitalisation between the VEC and VNEC was 0.80
(95%CI:0.67–0.95). When stratified by age, the hazard ratio was
1.22 (95%CI 0.81–1.85) for children <90 days of age and 0.73
(95%CI 0.60–0.89) for children 90 days.
For LRTI hospitalisations the HR between VEC and VNEC was
1.32 (95%CI:1.14–1.53) (Fig. 3). The hazard ratio was larger for chil-
dren <90 days of age, HR 1.54 (95%CI 1.23–1.94), and not signifi-
cant for children 90, HR 1.18 (95%CI 0.97–1.44).Table 2
Overview of admissions in the study birth-cohorts. Asterisk (*) signifies incomplete follow


















2005 4,541 13,278 446 33.59 219 (
2006 4,668 13,658 415 30.39 176 (
2007 4,770 13,985 423 30.25 186 (
2008 4,953 14,472 442 30.54 117 (
2009 5,130 14,965 484 32.34 124 (
2010 4,988 14,593 384 26.31 158 (
2011 4,643 13,638 392 28.74 129 (
2012 4,667 13,750 576 41.89 196 (
2013 4,438 13,033 472 36.22 149 (
2014* 4,440 10,916* 431* 39.48 144 (
2015* 4,026 6,027* 377* 62.55 105 (
Total 51,264 142,315 4,842 34.02 1,703Supplementary Table 1 shows the proportion of children diag-
nosed with pneumonia at the Children’s Hospital emergency room
that were admitted to hospital, length of stay and proportion of
admitted children transferred to ICU, stratified by birth-cohort.4.2. Admissions due to OM and other URTI
For URTI and OM, 123 children and 256 children had 131 and
280 hospitalisations, respectively. The crude IR of admission for
OM among children under three years of age was 2.32 and 1.45
per 1,000 person-years in the VNEC and VEC, respectively, and
the crude IR for URTI admissions was 0.78 and 1.13 in the VNEC
and VEC. The cumulative admission rate per 1,000 person-years
for URTI and OM are shown in Fig. 2.
The hazard ratio of OM admission between the VEC and VNEC
was 0.57 (95%CI:0.43–0.73). When stratified according to age
groups, the hazard ratio was 0.72 (95%CI 0.33–1.57), and 0.55
(95%CI 0.42–0.72 for <90 days and 90 days, respectively. The haz-
ard ratio for URTI hospitalisation was 1.56 (95%CI:1.11–2.19)
(Fig. 3). Among children <90 days, and 90 days, the hazard ratios
were 3.4 (95%CI 1.72–6.90) and 1.13 (95%CI 0.75–1.71),
respectively.4.3. Admissions due to all-cause meningitis and sepsis, and IPD
For meningitis and sepsis, 15 and 61 children had 19 and 63
hospitalisations, respectively. The crude IR for meningitis hospital-
isation was 16.5 and 8.7 per 100,000 person-years in the VNEC and
VEC respectively, and the crude IR for sepsis hospitalisations was
38.8 and 52.3. Twenty three hospitalised children had culture-
confirmed IPD. The crude IR for IPD was 24.7 per 100,000
person-years in the VNEC compared to 1.74 per 100,000 person-
years in the VEC. The proportion of IPD caused by vaccine-type
pneumococci was 77% in the VNEC and 0% in the VEC.
The cumulative admission rates per 1000 person-years for sep-
sis and IPD are shown in Fig. 2. For meningitis, the hazard ratio of
hospitalisation between the VEC and VNEC was 0.45 (95%CI 0.15–
1.41). The hazard ratio of hospital admission for IPD between VEC
and VNEC was 0.07 (95%CI:0.01–0.50). The hazard ratio of sepsis
hospitalisation between the VEC and VNEC was 1.26 (95%
CI:0.75–2.13) (Fig. 3). Survival analyses stratified according to
age for these three diagnostic groups did not alter results (data
not shown).-up due to censoring at the end of the study period before all children in the birth-
ssions, n
ren, n)






160) 16.49 49.1 7 (7)
140) 12.89 42.4 10 (8)
160) 13.30 43.9 6 (5)
101) 8.08 26.5 5 (4)
109) 8.29 25.6 7 (6)
138) 10.83 41.1 7 (7)
112) 9.46 32.9 4 (4)
155) 14.25 34 0 (0)
119) 11.43 31.6 9 (8)
122)* 13.19 33.4 6 (5)*
98)* 17.42 27.9 3 (3)*
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Fig. 1. Crude incidence rates (IR) of the six diagnostic groups (A-F) per 1,000 person-years for each of the birth-cohorts. Fig. 1 A–D and F depict the incidence rate of
admissions due to corresponding diagnosis, while Fig. 1E depicts the incidence rate of admissions with culture confirmed IPD, regardless of diagnosis. The comparison is split
into 6-month age-brackets which are illustrated in the Y-axis. The vaccine non-eligible cohorts (VNEC) are illustrated in light-gray and the vaccine eligible cohorts in dark-
gray.
Table 3
Comparison of the number of hospitalisations and the incidence rates of hospitalisations for individual ICD-10 diagnoses of the pneumonia diagnostic group. Incidence rate ratios
between the Vaccine eligible and Vaccine non-eligible cohorts are shown.
Sub-group diagnosis Vaccine non-eligible
cohorts
Vaccine eligible cohorts Comparison between
VEC and VNEC
n IR (95%CI) n IR (95%CI) IRR (95%CI)
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This population-based study of eleven consecutive birth-
cohorts demonstrated a 20% reduction in pneumonia hospitalisa-
tions among children younger than three years of age, following
the introduction of PHiD-CV into the national immunisation pro-
gram. Hospitalisations due to culture-confirmed IPD decreased by
93% and there were no hospital admissions due to vaccine-type
IPD among the vaccine eligible cohorts.The 20% impact of the PHiD-CV for all-cause pneumonia hospi-
talisations is in line with previous studies, which have demon-
strated a 7.4–30% reduction for clinically diagnosed pneumonia
[2,12,19,20].
As in any vaccine ecological study, careful consideration must
be paid to the possibility of unmeasured confounders. By including
all children in Iceland for eleven consecutive birth-cohorts, sam-
pling bias could be excluded. This means that differences in the
distribution of risk factors among children in the VNEC compared
Fig. 2. Kaplan-Meier cumulative event curves per 1,000 person-year for each of the diagnostic groups (A-F). The vaccine non-eligible cohorts (VNEC) are illustrated in blue
and the vaccine eligible cohorts (VEC) are illustrated in red. Censored observations are depicted with a cross and the 95% confidence intervals (CI) are represented by a shaded
area. The Y-axis is scaled independently for each pair of diagnostic groups (A-B, C-D and E-F). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
S. Sigurdsson et al. / Vaccine 38 (2020) 2707–2714 2711to VEC could only be due to systematic changes in the whole pop-
ulation. We are unaware of any systematic changes that could have
reduced the incidence of paediatric pneumonia requiring hospital-
isation, except the introduction of PHiD-CV. Temporal changes in
referral habits of pneumonia cases could possibly explain the
observed association, if physicians who previously tended to admit
low-risk paediatric pneumonia, later tended to treat them as out-
patients. If this was true, hospitalisations for other related diseases
would be expected to decrease concurrently, due to comparative
cultural change. The proportion of pneumonia hospitalisations
admitted to the ICU and the hospital length of stay would be
expected to increase, as the proportion of serious pneumonia caseswould be higher. None of these predictions were observed (Table 2,
Supplementary Table 1). In addition, we have demonstrated that
visits to the emergency department for pneumonia decreased after
the vaccination [16]. A possible confounder is a shift in coding
practices. In a recent Swedish study, comparing the use of ICD-10
discharge coding before and after introduction of PCV-7, a shift
from J12.1 (respiratory syncytial virus (RSV) pneumonia) to J21.0
(RSV bronchiolitis) was observed. A 52% reduction in bacterial
pneumonia (J13-J18) in children <2 years of age was also observed,
suggesting that a part of that reduction might be a diagnostic shift
due to an increase in virology testing [21]. In our study, no change
was observed for viral pneumonia J12, while a 32% increase was
Fig. 3. Hazard ratio between the vaccine eligible cohorts (VEC) and the vaccine non-eligible cohorts (VNEC) for each of the diagnostic groups. The point estimate is illustrated
as a point and the 95 percent confidence intervals (CI) are depicted with error-bars. The vertical dotted line represents the equivalency border of a hazard ratio of 1.
2712 S. Sigurdsson et al. / Vaccine 38 (2020) 2707–2714found in non-pneumonia LRTI (J20-J22). While differentiating
between clinical pneumonia and other LRTI in young children
can be challenging, we argue that the observed decrease in pneu-
monia is not the result of a drift in diagnostic coding practices,
for the following reasons. Firstly, only children admitted to the
paediatric ward were included, representing a subgroup with more
severe illnesses, that probably had greater number of diagnostic
tests done to confirm the diagnosis. This should reduce the risk
of misdiagnosis. Secondly, the increase in admissions due to LRTI
was only observed in children younger than six months of age,
while the decrease in pneumonia admissions was only noted in
children between 12 and 18 months of age. Similarly, when the
result of the survival analysis was stratified to children younger
than 90 days and older than 90 days the increase in non-
pneumonia LRTIs was attenuated in the <90 days old group, with
no significant change found in children >90 days of age. The same
trend could also be noted in the analysis for non otitis media URTI.
The opposite however was observed for the analysis on pneumonia
admissions, with no significant change noted in children <90 days
and an attenuated difference in children >90 days of age. This sug-
gests that the changes were independent, and not due to a shift in
diagnostic coding.
An increase in positive RSV and human metapneumovirus tests
was noted in Iceland [22] and other countries [23–26] in the post-
vaccination era. An increase in viral respiratory infections, such as
those caused by RSV, influenza and human metapneumovirus gen-
erally result in an increase in pneumococcal acquisition [27,28].
This may lead to subsequent bacterial diseases, including OM,
pneumonia and IPD [28–31].
There was a slight decrease in the incidence rate of pneumonia
hospitalisations in vaccine non-eligible birth-cohorts 2009 and
2010 aged 12–17 months (Fig. 1). This could be due to a combina-
tion of two factors, i.e. herd effect on the 2010 birth-cohort and
selective vaccination of high-risk children, which was imple-
mented in the years prior to vaccine introduction. This is supported
by our data, which show that 6% and 22% of children in the 2009
and 2010 birth-cohorts received the primary PCV doses before
their second birthday [18].
The 93% reduction observed in admissions due to IPD reported
in this study was greater than the 55–83% reduction in IPD
reported in other studies [12,32–37]. The decrease in IPD was evi-dent right from the beginning of the study period, before the vac-
cination program was introduced (Fig. 1). As it is a rare infection
occurring in a small population, year to year variations in IPD cases
can be considerable. Similar variations have been previously
reported on the incidence of meningitis in Iceland from 1975 to
2014 [38]. Some of the observed decrease could also be explained
by vaccination of at-risk children, as has been previously discussed.
The present study was not able to detect an impact on all-cause
meningitis and sepsis hospitalisations. This may be because of a
too small sample size to detect a change on diagnoses which are
less specific to pneumococcal disease than IPD and pneumonia.
A large reduction was found in admissions due to OM in the VEC
compared to VNEC. This appears to be due to a higher incidence of
OM hospitalisations among the first three vaccine non-eligible
birth-cohorts compared to all other study birth-cohorts, rather
than a decrease due to the introduction of the vaccine.
Three observational studies from the USA, Sweden and Italy
have demonstrated a decrease in OM hospitalisations following
the introduction of a PCV [14,15,39]. In an USA and a Swedish stud-
ies, the admission rates prior to the introduction of the PCV-7 vac-
cine was compared to rates following the introduction of PCV10/
PCV13 showing 66% and 42% reduction in hospital admission,
respectively [14,15]. In an Italian study a 36.4% reduction in OM
hospitalisation was noted in birth-cohorts eligible for the vaccina-
tion following PCV-7 introduction, compared to prior birth-cohorts
[39]. None of the above studies considered the impact of decreas-
ing trends in OM hospitalisations prior to the introduction of PCV
or the possibility of unmeasured confounding. In our study, the
importance of carefully interpreting the results with regard to tem-
poral trends and possible confounders was demonstrated to have
significant impact on the results. A recent Israeli study did not find
a decrease in hospital admissions due to OM [40].
Clinical practices in treating OM can vary greatly between coun-
tries and often depend on factors such as the feasibility of strict
follow-up. In Iceland, outpatient treatment of OM is favoured over
admissions whenever possible, with reassessment often scheduled.
While further studies are required to determine the full extent of
the impact of PCVs on OM admissions, the effect on OM in outpa-
tient care has been well established, including in Iceland
[11,17,41,42].
S. Sigurdsson et al. / Vaccine 38 (2020) 2707–2714 2713When comparing only children too young to have receive the
first primary does of the vaccine, no herd effect was noted for
any of the study diagnoses. However, the number of admissions
in that age group was low.
6. Conclusion
There was a significant impact of PHiD-CV on the rate of hospi-
tal admissions due to pneumonia and IPD among Icelandic children
younger than three years of age, adding to the growing literature
on the impact of PHiD-CV on pneumococcal diseases.
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